Feb 17, 2026 07:30AM
Nov 13, 2025 07:30AM
Nov 12, 2025 12:15PM
Nov 12, 2025 12:15PM
Nov 6, 2025 08:00AM
Aug 8, 2025 04:00PM
Aug 8, 2025 04:00PM Palatin Announces 1-for-50 Reverse Stock Split
May 14, 2025 07:30AM
May 9, 2025 07:30AM
May 9, 2025 07:30AM
May 8, 2025 10:19PM
May 8, 2025 04:39PM
May 7, 2025 08:01AM
May 7, 2025 08:00AM Palatin Technologies Announces Pricing of up to $23 Million Public Offering
May 5, 2025 07:30AM
Apr 29, 2025 07:30AM
Apr 29, 2025 07:30AM
Apr 17, 2025 07:30AM
Apr 17, 2025 07:30AM
Apr 10, 2025 07:30AM
Apr 10, 2025 07:30AM Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
Mar 31, 2025 07:36AM
Mar 31, 2025 07:30AM
Mar 28, 2025 07:30AM
Mar 28, 2025 07:30AM
Mar 25, 2025 07:31AM
Mar 25, 2025 07:30AM
Feb 13, 2025 07:30AM Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Feb 7, 2025 08:00AM
Feb 7, 2025 08:00AM
Feb 6, 2025 07:32AM
Feb 6, 2025 07:30AM
Jan 28, 2025 07:31AM
Jan 28, 2025 07:30AM
Dec 19, 2024 07:31AM Palatin Technologies (PTN) Announces Positive Phase IIb BREAKOUT Study Results
Dec 19, 2024 07:30AM
Dec 16, 2024 07:31AM
Dec 16, 2024 07:30AM
Nov 25, 2024 07:30AM
Nov 14, 2024 07:30AM
Nov 4, 2024 07:30AM
Oct 31, 2024 07:30AM Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Oct 24, 2024 07:30AM
Oct 23, 2024 07:30AM
Oct 1, 2024 07:32AM
Oct 1, 2024 07:30AM
Sep 9, 2024 07:31AM
Sep 9, 2024 07:30AM
Aug 28, 2024 07:30AM Palatin Technologies (PTN) Reports FDA Confirmed Acceptability of Remaining Phase 3 Trials for PL9643
Aug 28, 2024 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All